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Abstract
Background: Consistent healthcare decisionmaking requires systematic consideration of decision criteria and
evidence available to inform them. This can be tackled by combining multicriteria decision analysis (MCDA) and
Health Technology Assessment (HTA). The objective of this study was to field-test a decision support framework
(EVIDEM), explore its utility to a drug advisory committee and test its reliability over time.
Methods: Tramadol for chronic non-cancer pain was selected by the health plan as a case study relevant to their
context. Based on extensive literature review, a by-criterion HTA report was developed to provide synthesized
evidence for each criterion of the framework (14 criteria for the MCDA Core Model and 6 qualitative criteria for the
Contextual Tool). During workshop sessions, committee members tested the framework in three steps by assigning:
1) weights to each criterion of the MCDA Core Model representing individual perspective; 2) scores for tramadol
for each criterion of the MCDA Core Model using synthesized data; and 3) qualitative impacts of criteria of the
Contextual Tool on the appraisal. Utility and reliability of the approach were explored through discussion, survey
and test-retest. Agreement between test and retest data was analyzed by calculating intra-rater correlation
coefficients (ICCs) for weights, scores and MCDA value estimates.
Results: The framework was found useful by the drug advisory committee in supporting systematic consideration
of a broad range of criteria to promote a consistent approach to appraising healthcare interventions. Directly
integrated in the framework as a “by-criterion” HTA report, synthesized evidence for each criterion facilitated its
consideration, although this was sometimes limited by lack of relevant data. Test-retest analysis showed fair to
good consistency of weights, scores and MCDA value estimates at the individual level (ICC ranging from 0.676 to
0.698), thus lending some support for the reliability of the approach. Overall, committee members endorsed the
inclusion of most framework criteria and revealed important areas of discussion, clarification and adaptation of the
framework to the needs of the committee.
Conclusions: By promoting systematic consideration of all decision criteria and the underlying evidence, the
framework allows a consistent approach to appraising healthcare interventions. Further testing and validation are
needed to advance MCDA approaches in healthcare decisionmaking.
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Making decisions about the appropriate allocation of
scarce healthcare resources is a necessary but difficult
task. It involves consideration of a number of decision
criteria, processing disparate streams of information and
balancing individual and group/jurisdictional perspec-
tives, not to mention ethical principles [1]. This complex
process demands transparency, consistency, and
accountability to be perceived as legitimate by the public
and healthcare providers and to increase the likelihood
of making good decisions [2,3].
Cost-effectiveness analysis (CEA), an economic
method that aims to maximize efficiency, is the para-
digm that currently dominates many healthcare policy
decisionmaking processes. However, while potentially
useful as a measure for productivity in healthcare, [4]
sole reliance on CEA fails to address broader societal
and political issues, such as disease severity, availability
of alternatives, equity, and budget impact [4,5]. Even
agencies that espouse the cost-effectiveness paradigm,
such as NICE, acknowledge that other factors are being
considered in their decisions;[5,6] however, these factors
are not consistently integrated into the decisionmaking
process and not revealed in a transparent fashion [5].
There are additional concerns surrounding the CEA
paradigm, particularly the approach centered on the
cost per quality-adjusted life-year (QALY), including
methodological difficulties in valuing health states and
fundamental ethical questions regarding the underlying
objectives and outcomes of the approach [4,5]. Further,
the complexity of some economic models can hamper
understanding by the public and even by some decision-
makers of the key issues involved in the decision [6].
There is a need for a process that systematically and
explicitly addresses all key factors impacting decisions,
while promoting transparency and consistency in
decisionmaking.
Multicriteria decision analysis (MCDA), an emerging
tool in healthcare decisionmaking, goes beyond CEA by
allowing systematic and explicit consideration of multi-
ple factors that may impact the decision [1,7-10].
MCDA structures complex problems into a comprehen-
sive set of criteria. Each criterion is weighted –as t e p
that allows decisionmakers to clarify their fundamental
objectives and perspectives [11]– and the performance
of each healthcare intervention with respect to each cri-
terion is scored allowing identification of weaknesses
and strengths [1,7-9]. Although MCDA may be per-
ceived as not intuitive and potentially usurping decision-
making authority, if kept simple, it facilitates an
important dialog and forces decisionmakers to think
hard about and clearly express what they value, why
they value it, and in what context they value it.
In addition to the emergence of MCDA, recent dec-
ades have seen growth in the field of Health Technology
Assessment (HTA) [12]. With a mission “to assist and
advise healthcare decisionmakers in defining health poli-
cies at all levels”, [13] HTA acts as a bridge between evi-
dence and decisionmaking to ensure better synthesis,
communication and dissemination of information [14].
It is now widely recognized that to fulfill its mission, in
addition to clinical and economic factors, HTA needs to
address social, organizational, ethical and legal dimen-
sions of health technology [15-18]. Current efforts to
develop international standards for HTA reports [19,20]
point to the need for a structured format that can pro-
vide full access to the underlying evidence, thereby
enhancing transparency and usability of the report to
decisionmakers and stakeholders.
MCDA, HTA, and knowledge translation have a com-
mon objective: enlightened and evidence-based health-
care decisionmaking. Reflection on the drivers behind
healthcare decisions is essential to ensure that these
fields of research are aligned with the practical needs of
decisionmakers. A pragmatic framework (EVIDEM),
proposes a standard set of criteria with detailed metho-
dology i) to provide validated synthesized evidence for
each criterion (by-criterion HTA report), and ii) to sys-
tematically consider each criterion using a MCDA Core
Model and a Contextual Tool [21]. Criteria were defined
based on an extensive analysis of the literature and deci-
sion processes around the world, as well as discussion
with stakeholders; tools were developed to stimulate
reflection on priorities, to support systematic delibera-
tion and to facilitate pragmatic knowledge transfer
[21,22].
The EVIDEM framework underwent proof-of-con-
cept evaluation by a panel composed of a broad range
of Canadian stakeholders appraising 10 medications
[23]. As a support for policy decisionmaking, the fra-
mework was field-tested with the reimbursement advi-
sory committee of a private health plan in South
Africa using a cervical cancer screening tool as a case
study [24]. For clinical decisionmaking, the framework
was tested by a panel of pediatric endocrinologists and
other Canadian stakeholders using growth hormone
for Turner syndrome as a complex case study with far
reaching ethical issues; this study led to further devel-
opment of the framework and explicit integration of
ethical and system-related criteria into the decision
p r o c e s s[ 2 2 ] .T h eo b j e c t i v eo ft h i ss t u d yw a st of i e l d -
test a MCDA-based framework (EVIDEM), explore its
utility to a drug advisory committee and test the stabi-
lity of estimates over time using tramadol for chronic
non-cancer pain (CNCP) as a case study relevant to
their context.
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Study design
In a move to build on existing decisionmaking pro-
cesses, the EVIDEM framework was field-tested by the
Drug Advisory Committee of the Ontario Workplace
Safety Insurance Board (WSIB), which provides benefits,
including healthcare benefits, to workers suffering injury
or illness directly related to work. Tramadol for CNCP
was selected by the committee as a relevant case study
to the context of the population covered by the WSIB.
The study design is presented in Figure 1. Based on an
extensive literature review, a structured HTA report on
tramadol for CNCP was produced, tailored to provide
detailed information, as available, for each criterion of
the EVIDEM framework, i.e., 14 criteria for the MCDA
Core Model and 6 qualitative criteria for the Contextual
Tool [21,22]. Synthesized data integrated in the MCDA
Core Model and the Contextual Tool is referred to as
the “by-criterion HTA report”. During workshop ses-
sions, committee members tested the framework in
three steps by assigning: 1) weights to each criterion of
the MCDA Core Model representing individual perspec-
tive; 2) scores for tramadol for each criterion of the
MCDA Core Model using synthesized data (by-criterion
HTA report); and 3) qualitative impacts of the Contex-
tual Tool criteria on the appraisal. Utility and reliability
of the approach were explored through discussion, sur-
vey and test-retest.
By-criterion Health Technology Assessment report
An extensive analysis of the published and grey litera-
ture was performed to identify relevant data for each
Committee
Members
Retest on-line
MCDA Core Model
Step 1: Weight criteria of Core Model 
Step 2: Score intervention
Discussion and survey
Investigators
Case study
Tramadol for non-cancer pain in Canada
Contextual Tool
Step 3: Impact of contextual criteria 
on appraisal
Literature review
Synthesized evidence 
¾For each criterion of the 
framework
Quality assessment
¾Critical analysis of 
key evidence
By-criterion HTA report (web prototype)
Figure 1 Study plan.
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searches, including PubMed, EMBASE, Cochrane, Dis-
ease Association web sites (Canadian Pain society;
Chronic Pain Association of Canada), and websites of
the Agency for Healthcare Research and Quality
(AHRQ), the National Institute for Clinical Excellence
(NICE), the Canadian Agency for Drugs and Technolo-
gies in Health (CADTH), and the World Health Organi-
zation (WHO), were completed by hand searching of
bibliographies. Search terms included: tramadol, opioid/
NSAID/COX-2, chronic pain, chronic non-cancer pain,
osteoarthritis/low back pain/neuropathic pain/fibromyal-
gia, randomized controlled trial/non- randomized trial,
WOMAC/Pain and sleep Questionnaire/Chronic Pain
Sleep Inventory, abuse/dependence, quality of life/QoL/
HRQoL, epidemiol*/prevalence/incidence, mortality,
guideline/recommendation/clinical practice, pain man-
agement, patient- reported outcomes*/PRO, burden,
depression/anxiety, cost*/econom*, productivity, ethic*.
To provide the most relevant data to the committee,
evidence in the Canadian context was researched, supple-
mented with information from other countries. Disease
information was obtained from prominent reviews and
epidemiological studies in Canada and elsewhere. Ana-
lyses of the limitations of current options and of current
clinical guidelines for pain management in Canada and
elsewhere were performed. Clinical, safety and patient-
reported outcomes (PRO) evidence for tramadol and
comparators for the most important primary outcomes
[25,26]) were obtained from active-controlled rando-
mized clinical trials (RCTs) and product monograph.
Although inclusion of observational studies can supple-
ment evidence from RCTs, [27,28] no such studies were
identified. Economic data was obtained from the litera-
ture supplemented by analyses provided by the health
plan. Critical analysis of key clinical and economic stu-
dies was performed using the EVIDEM tools described
previously [21] to explore the quality of evidence. For the
contextual criteria, scientific and grey literature was
searched for information on ethical, historical, and con-
textual aspects of tramadol and opioid treatment.
Data collected was synthesized for each criterion of
the framework following the EVIDEM methodology [21]
based on HTA best practices recommendations (Busse
et al., 2002 [29]). To streamline access to evidence and
limit data overload, an interactive web prototype (Tiki-
wiki v3.0) was developed to provide highly synthesized
data for each criterion (’Lite’ version, for a quick grasp
of issues), hyperlinked to a version with more details
(’Full’ version) with further hyperlinks to the full text
sources from which data was extracted. The web proto-
type was also designed to allow committee members to
enter weights, scores and impacts for each criterion for
online appraisal of the selected medicine.
Field-testing with committee
To explore individual perspectives, during the workshop
session (test), each member of the committee (n = 9)
were instructed to assign weights individually (on a
scale of 1-low to 5-high) to each criterion of the MCDA
Core Model, from their perspective in the context of the
health plan. For consistency across interventions, com-
mittee members were instructed to attribute these
weights independently of the intervention; these weights
are expected to be defined once and then used through-
out appraisals.
Time was allotted on an as-needed basis. This was fol-
lowed by a period of discussion on each criterion, and
committee members were allowed to modify their
weights, on an individual basis.
To appraise the intervention, committee members
were instructed to score individually (on a scale of 0 to
3) each criterion of the MCDA Core Model, using evi-
dence synthesized for each of them (by-criterion HTA
report). This was followed by a period of discussion on
each criterion, and committee members were allowed to
modify their scores, on an individual basis.
Committee members then explored the six contextual
criteria and assigned the type of impact (negative, none
or positive) each criterion would have on the appraisal
of tramadol, using the colloquial and scientific evidence
integrated into the Contextual Tool.
Feedback on the framework, included criteria and pro-
cess was collected during discussion periods at the first
w o r k s h o pa n da taf o l l o w - u pw o r k s h o p ,a n df r o ma
questionnaire administered during the follow-up work-
shop. To explore reliability, a retest was performed at
least two weeks after the last session either using the
web-based prototype on-line or a hardcopy document.
Data collection and analyses
For the test, weights, scores and impacts were obtained
using the hardcopy documents distributed to committee
members and entered into Microsoft Excel software.
Data entered on-line by panelists (retest) was recorded
in a MySQL database and transferred to the Excel soft-
ware, which was then used to perform statistical
analyses.
Descriptive statistics were used and mean ± standard
deviations (SD) were reported for weights and scores.
The MCDA value estimate of the perceived value of
tramadol for the treatment of CNCP was obtained by
applying an MCDA linear additive model to combine
weights and scores [30]. The MCDA value estimate is
anchored on a scale of no value (0, e.g., minor symptom
relief for a rare, mild condition with numerous alterna-
tive treatment options that provides worse efficacy,
safety and quality of life and produces no public health
benefits but results in major additional spending) to
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Page 4 of 13maximum value (1, e.g., cure for an endemic severe dis-
ease with limited treatment alternatives that provides
significant improvement in efficacy, safety and quality of
life, and produces major public health benefits and
healthcare savings) [21].
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The estimate was thus calculated as the sum of value
contribution (Vx) of combined normalized weights (Wx)
and scores (Sx) for applicable criteria (n = 14) of the
MCDA Core Model. Calculations were performed for
each committee member (e.i., combining weights and
scores for each individual) and then averaging the
MCDA value estimates for the 9 committee members.
Agreement between test and retest data was analyzed
by calculating intra-rater correlation coefficients (ICCs)
for weights, scores and MCDA value estimates. One
type of ICCs was calculated following Shrout and Fleiss
(1979) [31] methods and classification: the ICC (3, 1)
which is based on a two-way mixed analysis of variance
(ANOVA) model (general effects of the test and the ret-
est were assumed to be fixed). In addition, the propor-
tion of data pairs that did not differ between test and
retest, that differed by 1 point, and that differed by 2
points, was calculated for weights and scores.
Inter-rater correlation coefficients were not calculated
since the tool is designed to capture individual perspec-
tives, which are expected to vary among individuals.
Results
By-criterion Health Technology Assessment report
Synthesized data was based on 69 references covering all
the criteria of the framework. The highly synthesized
version of the by-criterion HTA report with assessment
scales is reported in Additional file 1. The web HTA
report with all levels of synthesis is available online [32].
The report provides an overview of tramadol, a weak
opioid indicated for the treatment of CNCP, and the
context of this treatment in Canada. In summary, CNCP
is a disabling condition affecting 25% of the Canadian
population [33]. Efficacy and safety of current treat-
ments are limited due to ceiling effects and the potential
for organ damage [34-46].. In randomized trials, trama-
dol significantly reduced pain intensity from baseline,
but this reduction was not significantly different from
NSAIDs, COX-2 inhibitors and opioids [47-51]. The tol-
erability of tramadol is comparable to that of other
analgesics, [47,49,51-56] but drug abuse may be lower
with tramadol than with other opioids [57,58]. Signifi-
cant changes from baseline were observed for patient-
reported outcomes, which were not significantly differ-
ent than those reported for comparators, including pla-
cebo [47,48]. Relevance and validity of trial data was
limited by: the trial population (mostly older patients
with osteoarthritis (OA) not relevant to WSIB); trial
durations (a few weeks), high attrition rates in 3 trials
and unclear reporting in 2 trials.
Economic data indicated that, based on a daily cost of
tramadol of $2.24-2.27 (comparators costs range $0.11
to $6.61), reimbursement of tramadol would result,
depending on models assumptions, in savings of 0.32%
of additional expenditures and 0.27% of the current
budget for pain analgesics for the health plan budget
[unpublished data]. A Dutch cost-minimization analysis
indicated that, compared to NSAIDs, tramadol would
result in savings of $534 to $574 per patient over six
months when considering adverse events associated with
NSAIDs [59]. Relevance and validity of this study were
limited by the setting and OA population, a short time
horizon and costs considered (e.g., no costs from pro-
ductivity losses). To stimulate reflection and discussion
in the context of the health plan, information was pro-
vided in the Contextual Tool on: the utility of the treat-
ment, [60,61] its efficiency and potential opportunity
costs, fairness and access to care for opioid analgesics,
[61,62] risk of abuse, [57,63,64] pressures from the
Canadian Pain Society to keep tramadol out of the con-
trolled drug schedule, [65,66] historical reviews of the
WHO on tramadol [67] and recommendations on tra-
madol from Canadian agencies. This report was used for
field-testing of the framework with the committee.
Field-testing with committee
Decision criteria and committee perspective - weights
Independently of the specific case of tramadol, each
member of the committee assigned weights on a scale
of 1 to 5 to the criteria of the MCDA Core Model to
express individual perspectives. Mean weights and stan-
dard deviations are reported in Figure 2. At the commit-
tee level, the greatest importance was given to the
criteria “Improvement of efficacy/effectiveness” (4.6 ±
0.5) and “Relevance and validity of evidence” (4.3 ± 0.7).
The least important criterion was “Comparative inter-
ventions limitations” (3.1 ± 1.1). A perfect consensus
among committee members was observed for impor-
tance of the criterion “Disease severity” (SD: 0). Weights
for “Improvement of efficacy/effectiveness” and “Type of
medical service” also varied little among committee
members (SD: 0.5). The largest divergence of opinions
was recorded for the criterion “Comparative interven-
tion limitations” (SD: 1.1).
Survey data and discussion revealed that committee
members felt that most of the criteria considered in the
MCDA Core Model and the six contextual criteria were
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considered. Although the criterion “Disease severity”
was considered important by the committee (weight: 4.0
± 0), the necessity of this criterion was discussed; some
committee members noted that because of the type of
conditions covered by the health plan (i.e., work-related
illness or injury), scores for criterion “Disease severity”
may always be high in the committee context. However,
it was also noted that some of the population covered
by the health plan suffer from really severe diseases and
that the framework would capture this aspect. “Public
health interest” was considered by some committee
members as irrelevant in their context, and there was
some controversy on considering the criterion “Political/
historical context”.
MCDA Core Model - scores for tramadol
Using synthesized data integrated in the MCDA Core
Model and the Contextual Tool (by-criterion HTA
report) (Additional file 1), committee members assigned
scores to appraise tramadol for each criterion (Figure 3).
The highest scores were assigned to the criteria “Size of
population affected by disease” (2.6 ± 0.5, on a scale of 0
to 3), “Disease severity” (1.9 ± 0.3) and “Impact on other
spending” (1.8 ± 0.4). In contrast, low scores were given
to “Improvement of patient-reported outcomes” (0.9 ±
0.3), “Improvement of efficacy/effectiveness” (1.0 ± 0.0)
and “Improvement of safety & tolerability” (1.0 ± 0.5).
The committee demonstrated a unanimous agreement
concerning the performance of tramadol with respect to
“Improvement of efficacy/effectiveness” (SD: 0.0). In con-
trast, differences of 2 and 3 points (on a scale of 0 to 3)
were observed for “Type of medical service” (SD: 0.8) and
“Comparative intervention limitations” (SD: 0.7), respec-
tively. Committee members indicated that average scores
for the MCDA criteria presented in Figure 3 had good
face validity and represented their opinion of tramadol.
The scoring direction for the criterion “Size of the
population”, which stipulates a higher score for inter-
ventions for conditions with high prevalence/incidence,
was questioned as committee members felt that inter-
ventions for rare conditions should not be valued lower
than those for more common conditions. Committee
members also raised the importance of patient prefer-
ences and their perspective on the disease, which could
be more explicitly considered under the criterion
“Patient-reported outcomes”. When evaluating the cri-
terion “Improvement of efficacy/effectiveness”, commit-
tee members noted that while they consider RCTs are
the primary sources of data on efficacy, non-randomized
studies can sometimes be useful for providing supple-
mentary information on safety and real-life effectiveness.
MCDA Core Model - value estimate for tramadol
The MCDA value estimate for tramadol, which inte-
grates perspectives of committee members (weights) and
Figure 2 Mean weights for decision criteria of the MCDA Core Model from the drug advisory committee. A five-point weighting scale
was used with 1 for lowest weight and 5 for highest weight.
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each member of the committee by combining normal-
ized weights and scores using a linear additive model.
At the individual level, the MCDA value estimates ran-
ged between 0.36 and 0.61 on a scale of 0 to 1. For the
group, the overall MCDA value estimate was 0.44 ±
0.07. More than one quarter (26%) of the estimated
value of tramadol was derived from the two criteria of
the “Disease impact” cluster ("Disease severity” and “Size
of population”) (Figure 4). Relative contributions of the
other criteria to the MCDA value estimate for tramadol
ranged between 5% and 8%.
Committee members indicated that quantification of evi-
dence and interpretation of the MCDA value estimate of
0.44 was challenging and required detailed explanations on
mathematical calculations used in the framework. It was
deemed difficult to interpret the end result of the MCDA
Core Model. Scaling with other drugs appraised by the
committee (preferably with widely differing MCDA value
estimates) would be needed to clarify the meaning of
MCDA value estimates and get a better grasp of how the
methodology can be used for ranking interventions. Some
committee members expressed reluctance to base decisions
on cut-off values, which is not the objective of the frame-
work, as it allows for qualitative contextual considerations
to modulate the estimate (see section below - Contextual
Tool). In addition, the framework is meant to support the
evaluation and deliberation leading to the decision, which
was deemed very important by the committee.
Contextual Tool - impacts of contextual criteria on
tramadol appraisal
Based on the synthesized information collected for the
six contextual criteria (Additional file 1) and their own
understanding of the context, committee members con-
sidered what type of impact (positive, negative or neu-
tral) each contextual criterion would have on the
appraisal of tramadol. The distribution of these impacts
within the committee is shown in Figure 5.
For most committee members (8 out of 9), “Goal of
healthcare - utility” had a positive impact on the apprai-
sal of tramadol, since relieving pain is aligned with the
goals of healthcare in general and the WSIB in particu-
lar. Regarding the criterion “System capacity and appro-
priate use of intervention” opinions were divided (5
indicated a positive, 4 a neutral impact), as committee
members indicated: that “abuse with tramadol exists";
that there is a “need for abuse data for the true com-
parator (e.g., codeine) rather than with more potent
hydrocodone which is a misleading comparison"; but
that there is a “growing concern/burden about opiate
abuse and any drug with potential to decrease that bur-
den deserves special consideration”.
Figure 3 Mean scores for decision criteria of the MCDA Core Model for the appraisal of tramadol by the drug advisory committee.A
four-point scoring scale was used with 0 for lowest score and 3 for highest score.
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negative impact on the appraisal for most (7 out of 9)
committee members as it was noted that “tramadol is
more expensive than comparable medicines”.F o rm o r e
than half of committee members (5 out of 9), “Political/
historical context” had a negative impact on the apprai-
sal of tramadol. As stated by one committee member
“negative recommendations from other agencies have a
negative impact on tramadol”.
Regarding “Population priority and access and fair-
ness”, 5 out of 8 committee members indicated that this
criterion had no (neutral) impact on the appraisal. One
member did not provide data for this criterion and indi-
cated that it was not clear how to consider it, highlight-
ing the need for thorough reflection on this criterion
which is meant to elicit discussion on priorities of the
health plan. Impacts were mixed for “Stakeholders
pressures”.
Explicit consideration of the six contextual criteria
forced reflection on a broad range of issues, which were
considered to have mixed impacts on the overall apprai-
sal of tramadol.
Feedback from committee on overall approach
Participants indicated that the framework is a good
point of departure to help lead group discussions and to
ensure systematic, transparent and consistent considera-
tion of important elements that may affect decisionmak-
ing. To cite one committee member: “EVIDEM is a
good tool in the sense that it forces each member to
think and weight aspects that otherwise would not have
been considered”. Another committee member felt that
Figure 4 MCDA value estimate of tramadol for chronic non-cancer pain. Weights were normalized across the 14 criteria and scores are
presented on a scale of 0 to 1. *MCDA value estimate was obtained using a linear model combining normalized weights and scores for each
decision criterion. For an intervention to achieve close to 1 on this scale, it would have to cure an endemic disease, demonstrate major
improvement in safety, efficacy, and patient-reported outcomes compared to limited existing approaches and result in major healthcare savings.
Tony et al. BMC Health Services Research 2011, 11:329
http://www.biomedcentral.com/1472-6963/11/329
Page 8 of 13it may help validate decisions and demonstrate transpar-
ency to stakeholders. Some members voiced concern
about the amount of work involved in developing the
by-criterion HTA report. Others questioned the com-
plexity of the tool and terminology used. One commit-
tee member stated that the framework adds clarity to
decisionmaking but repeated use may be required to
fully capture its utility and get acquainted with its
application.
Exploration of reliability
Weighting and scoring during the test and the retest
led to the same mean MCDA value estimate of 0.44
(Table 1). The ICC (3, 1) for these data was 0.698,
indicating fair to good reproducibility. ICC (3, 1)
values of 0.683 for weights and of 0.676 for scores
were also a sign of good reliability of test-retest
weights and scores.
Between test and retest, 65.1% of weights were identi-
cal, 31.7% differed by 1 point (on a scale of 1 to 5) and
3.2% differed by 2 points. The greatest inconsistency
between test and retest weights was recorded for the
cluster “Context of intervention” (38.9% identical) and
the least for the clusters “Disease impact” and “Interven-
tion outcomes” (77.8% identical).
Scores exhibited better consistency between test and
retest than weights: 78.8% were identical, 19.8% differed
by 1 point (on a scale of 0 to 3) and 1.6% differed by 2
points. The greatest difference between test and retest
was recorded for clusters “Context of intervention” and
“Type of benefits” (61.1% identical) and the least for
clusters “Disease impact” and “Quality of evidence”
(88.9% identical).
Discussion
The framework was found useful by the drug advisory
committee in supporting systematic consideration of a
broad range of criteria to promote a consistent approach
to appraising healthcare interventions. Directly inte-
grated in the framework as a “by-criterion “ HTA
report, synthesized evidence for each criterion facilitated
its consideration, although this was sometimes limited
by lack of relevant data. This is in agreement with pre-
vious studies in which committee members and pane-
lists indicated that the framework was a useful approach
to systematic consideration of all aspects of decision,
facilitating consistency, transparency and clarity of
appraisal and decisionmaking [22,24]. Test-retest analy-
sis showed fair to good consistency of weights, scores
and MCDA value estimates at the individual level (ICC
ranging from 0.676 to 0.698), thus lending some support
for the reliability of the approach. Overall, committee
members endorsed the inclusion of most framework cri-
teria and revealed important areas of discussion, clarifi-
cation and adaptation of the framework to the needs of
the committee.
The EVIDEM framework is aligned with the four key
features of HTA identified by Battista et al.:[14] policy
orientation; interdisciplinary content and process; synth-
esis of information; and facilitation of dissemination and
communication of information. The framework pro-
poses a comprehensive set of criteria to promote sys-
tematic and explicit consideration of all aspects of
decision, including ethical and system-related issues,
considered vital for HTA to fulfill its mandate [68].
Testing revealed the need for adjusting criteria and pro-
cesses to ensure MCDA approaches can support existing
Figure 5 Impact of contextual criteria on tramadol appraisal by the drug advisory committee.
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framework is meant to be adapted and some tools have
been developed since to facilitate adaptation of the fra-
mework based on collaborative development with users
and researchers [69].
Standardized procedures for gathering, synthesizing,
distilling, and presenting information to inform each cri-
terion, an integral part of the framework, can also con-
tribute to enhancing consistency of the decisionmaking
process. As advocated by Straus, [70] Robeson [71] and
their coworkers, data was made available on the web in
two hyperlinked levels: a ‘lite’ version with data distilled
into key messages –to facilitate knowledge transfer and
to reduce the time required to integrate the information
presented– and a comprehensive, detailed synthesis with
full access to underlying sources of evidence. Although
presenting the data at these two levels of synthesis was
found to be helpful by some committee members,
others would have preferred the ‘lite’ version to provide
more details. Thus, while the comprehensive version of
the by-criterion HTA report should always serve as a
basis, subsequent knowledge distillation may need to be
further optimized to strike the right balance between
conciseness and detail. Collaborative development is
ongoing to further advance the methodology to synthe-
size data for each criterion and for different levels of
details.
The weighting exercise and following discussion
revealed the different perspectives of committee mem-
bers as captured by the large SDs for some criteria. Var-
iations may also be due to different understanding of
the criteria, although detailed definitions were provided
and were further clarified during discussions. For consis-
tency across interventions, it is recommended that these
weights be attributed once and then used throughout
appraisals. Although at the individual level, relative
weights vary largely between criteria, once weights are
averaged at the committee level, extremes disappear and
weights tend to be less distinguishable. Exploration of
how the weight elicitation methods (e.g., analytical
hierarchy process [AHP], Simple Multi-Attribute Rating
Technique [SMART], point allocation, ranking)[72],
impact weight attribution and the overall MCDA value
estimate is ongoing to further advance the approach and
provide additional tools to adapt the framework to the
preferences and needs of users.
Interpretation and utility of the MCDA value estimate
(i.e., the figure 0.44) was found challenging by commit-
tee members. Indeed, the MCDA value estimates are
meant to be used in a comparative manner for ranking
healthcare interventions, which was beyond the scope of
this case study. An MCDA model adapted from the
EVIDEM framework by a district health board uses such
an approach to systematically evaluate and prioritize a
wide range of healthcare interventions (Sharon Kletchko,
MD, personal communication 2011). Although basic
principles are explicit, interpretation of the MCDA scale
requires acquaintance with the broad range of criteria
that are incorporated in a single number. For example,
an intervention with a score close to 1, which would
constitute a high-end reference point, would have to be
something like: a cure for an endemic severe disease
with limited or no alternatives that provides significant
improvement in efficacy, safety and quality of life, and
produces major public health benefits and healthcare
savings [21]. A pilot study testing the framework with
13 Canadian healthcare stakeholders showed that the
MCDA value scale had discriminating properties, with
mean estimates ranging from 0.42 to 0.64 across 10
medicines [23]. However, it should be kept in mind that
MCDA value estimates are not meant to be used in a
prescriptive fashion, but rather as “a framework condu-
cive for focused discussion.”[73] MCDA value estimates
can serve as a basis for establishing a ranking scheme,
[9] which can be modulated by ethical and context
related considerations. This is often done implicitly in
healthcare decisionmaking and is meant to be facilitated
by the Contextual Tool. It should also be noted that
MCDA value estimates obtained by applying this frame-
work are committee-specific since they reflect the
Table 1 Agreement at the individual level between test-retest for weights, scores and MCDA value estimates for
tramadol
Weights Scores Value Estimates
Number of test-retest pairs 126* 126* 9
Mean of test data 3.81 1.31 0.44
Mean of retest data 3.81 1.33 0.44
ICC (3, 1) 0.683 0.676 0.698
Proportion of pairs with no test-retest difference (%) 65.1 78.6 NA
Proportion of pairs with test-retest difference of 1 point (%) 31.7 19.8 NA
Proportion of pairs with test-retest difference of 2 points (%) 3.2 1.6 NA
*9 evaluators × 14 MCDA criteria
NA: Not applicable
ICC: intra-class correlation coefficient, defined according to Shrout and Fleiss (1979) [31]
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tured by weights.
Although there are numerous approaches to improve
healthcare coverage decisionmaking –including the pre-
vailing cost-effectiveness paradigm, program-budgeting
and marginal analysis, and the HTA Core Model
[74-76], for example – there is no accepted and vali-
dated way to identify successful evaluation and decision-
making and still less consensus concerning the best
framework to support decisionmaking [77] or even the
most reliable process for weight elicitation [78]. In that
sense, our study suffered limitations common to other
studies on the validity of decisionmaking approaches.
Exploration of reliability revealed good consistency at
the individual level which constitutes a first positive
step. Higher consistency with scores, which are based
on evidence, than with weights, which are based on
individual perspective, were observed in this study and
may reveal the difficulty to explicit its one’s perspective.
This might stem from the fact that perspectives are
often implicit and that decisionmakers need to reflect
on the implications of the criteria. As for every evalua-
tion of healthcare interventions, the information pre-
sented on the case study was limited by the information
available at the time of the study. Nevertheless, this field
study has shown that, through bridging HTA and
MCDA, the EVIDEM framework can support appraisal
in practice, particularly by promoting systematic consid-
eration of a comprehensive set of carefully selected cri-
teria. A strength of the framework also lies in the
acknowledgment and incorporation into its application
that decisionmaking is a “fundamentally value-laden
enterprise” [68]. These features are combined with firm
grounding in scientific evidence, which includes rigorous
synthesis and quality assessment, to make the commit-
tee’s deliberative process as well-informed, comprehen-
sive and explicit as possible. The framework promotes a
consistent approach to decisionmaking that can help
legitimize decisions and be aligned with the A4R frame-
work set forth by Daniels [79,80].
Conclusions
In a field test with a public health plan drug advisory
committee, the EVIDEM framework supported apprai-
sal and deliberations in practice by bridging HTA and
MCDA. Feedback from some committee members con-
firmed that the framework promoted the explicit con-
sideration of a wide range of criteria relevant to
decisionmakers. Further field testing is required to
establish a frame of reference for appraisal outcomes,
optimize and adjust its use in practice, and establish
consistency. Further research is needed to collabora-
tively advance pragmatic MCDA-based frameworks for
appraisal of healthcare interventions, decisionmaking,
priority setting and pragmatic knowledge translation.
Additional material
Additional file 1: By-criterion health technology assessment report
on tramadol (’Lite’ highly synthesized version). References for each
statement and links to sources are available on the web version of this
report [32].
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